Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Poon

Showing results (161-170 of 252) with videos related to

Pageof 26
Sort By:
Clinical Genitourinary Cancer|August 22, 2018
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong KongDarren M C Poon, Kenneth C W Wong, T W Chan, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|July 3, 2025
Survival estimate models of cancer patients with spinal metastases: big data analytics to aid daily clinical practice (abridged secondary publication)K Y H Kwan, C L Cheung, K M C Cheung, et al.
Quantitative Imaging in Medicine and Surgery|October 4, 2021
Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic reviewCindy Xue, Jing Yuan, Gladys G Lo, et al.
Prostate International|March 21, 2018
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 studyDarren M C Poon, Kuen Chan, Siu H Lee, et al.
Transfusion Medicine (Oxford, England)|April 11, 2008
The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy frameworkC J Moltzan, D A Anderson, J Callum, et al.
European Urology Oncology|December 22, 2025
Magnetic Resonance Imaging-guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysisDarren M C Poon, Jing Yuan, Bin Yang, et al.
BMC Urology|March 23, 2016
Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experienceDarren M C Poon, Kuen Chan, S H Lee, et al.
Asia-Pacific Journal of Clinical Oncology|March 7, 2018
Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index compositeTsz Kin Lee, Darren M C Poon, Anthony C F Ng, et al.
Nucleic Acids Research|July 1, 1993
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993F Giannelli, P M Green, K A High, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 20, 2013
Dosimetric advantages and superior treatment delivery efficiency of RapidArc over conventional intensity-modulated radiotherapy in high-risk prostate cancer involving seminal vesicles and pelvic nodesD M C Poon, M Kam, C M Leung, et al.
Pageof 26

Showing results (161-170 of 252) with videos related to

Sort By:
Pageof 26
Clinical Genitourinary Cancer|August 22, 2018
Survival Outcomes, Prostate-specific Antigen Response, and Tolerance in First and Later Lines of Enzalutamide Treatment for Metastatic Castration-resistant Prostate Cancer: A Real-World Experience in Hong KongDarren M C Poon, Kenneth C W Wong, T W Chan, et al.
Hong Kong Medical Journal = Xianggang Yi Xue Za Zhi|July 3, 2025
Survival estimate models of cancer patients with spinal metastases: big data analytics to aid daily clinical practice (abridged secondary publication)K Y H Kwan, C L Cheung, K M C Cheung, et al.
Quantitative Imaging in Medicine and Surgery|October 4, 2021
Radiomics feature reliability assessed by intraclass correlation coefficient: a systematic reviewCindy Xue, Jing Yuan, Gladys G Lo, et al.
Prostate International|March 21, 2018
Differences in clinical outcome between docetaxel and abiraterone acetate as the first-line treatment in chemo-naïve metastatic castration-resistant prostate cancer patients with or without the ineligible clinical factors of the COU-AA-302 studyDarren M C Poon, Kuen Chan, Siu H Lee, et al.
Transfusion Medicine (Oxford, England)|April 11, 2008
The evidence for the use of recombinant factor VIIa in massive bleeding: development of a transfusion policy frameworkC J Moltzan, D A Anderson, J Callum, et al.
European Urology Oncology|December 22, 2025
Magnetic Resonance Imaging-guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysisDarren M C Poon, Jing Yuan, Bin Yang, et al.
BMC Urology|March 23, 2016
Abiraterone acetate in metastatic castration-resistant prostate cancer - the unanticipated real-world clinical experienceDarren M C Poon, Kuen Chan, S H Lee, et al.
Asia-Pacific Journal of Clinical Oncology|March 7, 2018
Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index compositeTsz Kin Lee, Darren M C Poon, Anthony C F Ng, et al.
Nucleic Acids Research|July 1, 1993
Haemophilia B: database of point mutations and short additions and deletions--fourth edition, 1993F Giannelli, P M Green, K A High, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 20, 2013
Dosimetric advantages and superior treatment delivery efficiency of RapidArc over conventional intensity-modulated radiotherapy in high-risk prostate cancer involving seminal vesicles and pelvic nodesD M C Poon, M Kam, C M Leung, et al.
Pageof 26